Cartesian Therapeutics (RNAC) Misses Q3 EPS by 138c
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 EPS of ($1.38). Revenue for the quarter came in at $450 thousand.
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- STAAR Surgical (STAA) PT Lowered to $28 at Stifel After Net-Positive Earnings Call
- Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
